B2BROKER
18.11.2020 12:59:09 CET | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the Forex and crypto industry, has announced the launch of B2Margin , a white label margin exchange trading platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005593/en/
Margin trading, long present in the Forex markets, is now hugely popular in the fast-moving crypto sphere. Even large exchanges have now implemented leveraged trading thanks to its high profit-potential which is not achievable with spot trading these days.
B2Broker CEO and Founder, Arthur Azizov comments, “Margin trading has really increased in popularity despite the fact that derivative trading is what everyone tried to avoid when this was all starting out. Back in 2016, all traders preferred spot trading but business is now moving further towards derivative trading, justifying our decision to develop B2Margin and offer an attractive margin trading solution to our clients”.
Crypto margin trading offers brokers several compelling advantages in terms of more trading opportunities. The threat of exchange hacks is also minimised since trading with leverage reduces the amount of capital that is required to be held by an exchange.
About B2Margin
B2Margin is a White Label Margin Exchange trading platform developed by B2Broker that includes a range of functions including on-boarding, compliance, risk management, pricing and trading analytics.
Offering traders the opportunity to boost their trading with leverage, B2Margin is designed with both institutional and retail clients in mind, supporting multiple asset classes, such as FX, Metals, Indices, Energies, Stocks, ETFs, Cryptocurrencies CFDs and Spot/Cash Cryptocurrencies, with Futures Cryptocurrencies in the pipeline. This means that every broker will be able to provide two solutions to their clients - either leverage or cash trading on all the asset classes outlined.
Furthermore, B2Broker is in the final stages of completing its dividend distribution module which will allow broker-dealers to provide liquidity for STOs shares and cash equities.
Professional and Adaptive GUI
B2Margin offers a vast range of features with an advanced interface which meets all requirements from beginners to professional traders. By providing a customizable and adaptive layout, end users get to choose what they wish to see according to their needs and preferences. Trading instruments are grouped by classes with a customisable workspace which includes intuitive visualisation of market data, an extensive suite of trading tools and complete branding customisation. Some of the main features include:
Multiple Order Types
B2Margin offers multiple order types to support the most sophisticated trading strategies and provide users with a variety of options on how and when to enter and exit a trade. From Protection orders to Time in Force up to Pending orders, traders have everything they need to manage their trading activity.
Professional Сharts
This enables users to place trades, manage orders and work directly from our integrated charts and utilise a comprehensive suite of drawing tools, as well as over 50 technical indicators to analyze price trends.
Secure Wallets
The ability to withdraw, deposit and store your assets in your personal secure wallet. All assets are securely held in our offline storage system to protect users against any possible risks and threats.
Watchlist
Users have the opportunity to add their favourite instruments to the list and keep an eye on their current prices and 24 hour changes. Orders can then be placed straight from the Watchlist.
Order Book
The list of buy and sell orders organized by price is updated in real time and is an important indicator of market depth, reflecting the trading instrument's likely price trend.
Customised Leverage
For precise risk management, a broker’s clients can set their own custom leverage for each trade order. This is a highly anticipated unique feature that provides a competitive advantage in attracting clients to a business.
Risk Management
Along with the standard way of managing risk known as A-Book or B-Book, B2Margin allows brokers to use C-Book - a highly advanced feature for each broker’s dealing department.
A broker dealer will also be able to customise their spread, markup, swap and commissions for each user, particular accounts and by group.
Tech Support
B2Broker offers all its clients 24/7 technical support.
These features, with the added benefit of detailed account statements to volume trade reports, allow brokers to get complete control over their operations and maximise their business potential.
A Complete Customised Solution in 4 Weeks
A complete B2Margin brokerage solution can be implemented in under 4 weeks once the associated legalities and financial aspects are settled. B2Margin also includes B2Broker’s client traders room solution, B2Core , which allows for client onboarding, processing deposits and withdrawals, KYC and a host of other functions for a successful Brokerage business operation. Finally, B2Margin supports FIX API connection enabling brokers to offer their clients the ultimate in trading performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005593/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release
First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an
Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release
Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
